Han et al. compared gefitinib treatment in both sensitive and resistant lung cancer cell lines; interestingly, immunoblotting and immunofluorescent staining demonstrated an increase in both ATG5 and ATG7 levels and LC3II expression in resistant cell lines [74]. Here, ATG5 is linked to lung carcinoma.